Form 4: Acadia Pharmaceuticals CEO Stephen Davis Reports Stock Transactions

CEO Stephen Davis of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• Stephen Davis, CEO of Acadia Pharmaceuticals, reported transactions involving the company's common stock.
• On May 1, 2024, 22,391 restricted stock units vested, each representing a contingent right to receive one share of Acadia's common stock.
• Also on May 1, 2024, 22,391 shares were disposed of.
• On May 2, 2024, Davis sold 11,427 shares at a weighted average price of $16.94 per share, with prices ranging from $16.94 to $17.015.
• These sales were mandatory and intended to cover withholding taxes related to the vesting of the restricted stock units.
• Following these transactions, Davis directly owns 155,231 shares of Acadia Pharmaceuticals.
• The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This is a routine disclosure of insider transactions, which are common for executives who receive stock-based compensation. The sale was to cover tax obligations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by the CEO, but the impact is likely minimal as it was to cover tax obligations.

Key Dates